TY  - CONF

T1  - DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)-A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation

JO  - JOURNAL OF CLINICAL ONCOLOGY

PY  - 2022/01/01

AU  - Niazi T

AU  - McBride SM

AU  - Williams S

AU  - Davis ID

AU  - Stockler MR

AU  - Martin AJ

AU  - Bracken K

AU  - Roncolato F

AU  - Horvath L

AU  - Sengupta S

AU  - Martin J et al

ED  - 

VL  - 40

IS  - 16

Y2  - 2024/12/29

ER  -